Merck KGaA to Present P-III (MANEUVER) Trial Data of Pimicotinib for Tenosynovial Giant Cell Tumor at ASCO 2025

Shots:Part 1 of P-III (MANEUVER) trial assessed pimicotinib (n=63) vs PBO (n=31) for 24wks. in 94 TGCT pts who required systemic therapy & had no prior anti-CSF-1/CSF-1R treatment; trial also incl. an open-label Part 2 (data expected in mid-2025) & an OLE phase (Part 3)Trial met its 1EP of improved ORR (54.0% vs…

ByRidhi Rastogi3 days ago

News

Merck KGaA to Acquire SpringWorks Therapeutics for ~$3.9B

Shots:Merck KGaA has entered into a definitive agreement to acquire SpringWorks Therapeutics to strengthen its rare disease portfolio & expand SpringWorks’ reach to markets beyond the USAs per the agreement, Merck KGaA will acquire SpringWorks for $47/share (~26% premium), with an equity value of ~$3.9B or an enterprise value of ~$3.4B, funded by…

ByRidhi RastogiApril 28, 2025

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2024

Shots:The second quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Vertex’ acquisition of Alpine Immune Sciences for ~$4.9BThis quarter also showcased multiple clinical trial results including Moderna’s P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19…

BySenior EditorJuly 2, 2024

INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

Shots: Witness the journey of the biopharma companies over 20 years with this informative and engaging report. The report highlights the development of the biopharma industry and the key factors influencing them In 2023, JNJ reclaims the topmost position in the list from Pfizer with a revenue of $85.16B, showcasing a sharp 10.30 percent vs…

BySaurabh ChaubeyMay 1, 2024

THOUGHTSPOT

8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry

Shots:In the wake of International Labour Day, PharmaShots presents a detailed take on the recent layoffs in the Pharmaceutical Sector with an illustrative graphical analysisLike any sector, the pharmaceutical industry operates on some nuance and intricate aspects that ensure smooth operations. Factors like digitalization, patent expiry, growing competition, and others put direct or…

BySenior EditorMay 1, 2023

INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Shots:With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturingWhile major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…

BySenior EditorApril 13, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2022

Shots:The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6BIn the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

BySenior EditorDecember 29, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfoliosWhile top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229MThe key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…

BySenior EditorSeptember 30, 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2021

The US FDA has approved 7 NDAs and 1 BLA in Feb 2021, leading to treatments for patients and advances in the health care industry.The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 12 novel products in 2021.Additionally, last year in 2020, the US…

BySenior EditorMarch 18, 2021

Merck KGaA to Present P-III (MANEUVER) Trial Data of Pimicotinib for Tenosynovial Giant Cell Tumor at ASCO 2025

Merck KGaA to Acquire SpringWorks Therapeutics for ~$3.9B

PharmaShots’ Key Highlights of Second Quarter 2024

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

PharmaShots’ Key Highlights of Fourth Quarter 2022

Top 20 BioPharma Companies based on 2021 Total Revenue

PharmaShots’ Key Highlights of Third Quarter 2021

Insights+: The US FDA New Drug Approvals in February 2021

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter